Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 1:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 527 matching trials from the live ClinicalTrials.gov search.
Conditions
Pancreatic Cancer
Interventions
multiTAA specific T cells
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
3
States / cities
Houston, Texas
Conditions
Rectal Cancer, Non Metastatic Rectal Cancer
Interventions
ctDNA
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts • Newton, Massachusetts
Conditions
Bladder Carcinoma, Refractory Bladder Carcinoma, Urinary Tract Infection
Interventions
Clindamycin, Diary, Ertapenem, Levofloxacin, Nitrofurantoin, Trimethoprim-Sulfamethoxazole
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Buffalo, New York
Completed No phase listed Observational Results available

Utility of Novel BRAF Test for Melanoma

NCT01840527
Conditions
Melanoma
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
3
States / cities
Boston, Massachusetts
Conditions
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Relapsed/Refractory AML
Interventions
Bexmarilimab, Azacitidine, Venetoclax
Drug
Lead sponsor
Faron Pharmaceuticals Ltd
Industry
Eligibility
18 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Duarte, California • New Haven, Connecticut • Chapel Hill, North Carolina + 1 more
Completed Not applicable Interventional Results available

Preoperative Exercise in Pancreatic Cancer

NCT02648880
Conditions
Pancreatic Cancer
Interventions
Exercise program, Standard Care
Behavioral · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma
Interventions
cemiplimab, Platinum Doublet, fianlimab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
New York, New York
Conditions
Parkinson Disease
Interventions
DBS Programming
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Recruiting No phase listed Observational

Characterization of Acute Pain

NCT07336264
Conditions
Acute Pain, Postoperative, Postoperative Pain, Acute Pain
Interventions
AlgometRx Nociometer
Device
Lead sponsor
Children's National Research Institute
Other
Eligibility
6 Years to 21 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma
Interventions
Pembrolizumab, Defactinib
Drug
Lead sponsor
Lei Zheng
Other
Eligibility
18 Years to 100 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
3
States / cities
Los Angeles, California • Baltimore, Maryland • San Antonio, Texas
Conditions
Muscle Invasive Bladder Cancer
Interventions
Durvalumab, Tremelimumab, Enfortumab Vedotin, Radical Cystectomy
Drug · Procedure
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
712 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
31
States / cities
Orange, California • Santa Monica, California • New Haven, Connecticut + 28 more
Conditions
ACL Tear, Post Operative Pain
Interventions
Iovera, Celecoxib, Acetaminophen, Oxycodone, Tramadol, Bupivacaine Hydrochloride, Acetaminophen 500Mg Cap
Device · Drug
Lead sponsor
Matthew Varacallo
Other
Eligibility
15 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
DuBois, Pennsylvania
Conditions
Breast Cancer, Breast Carcinoma, Malignant Neoplasm of Breast
Interventions
Mammaglobin-A DNA Vaccine, Optional biopsy
Biological · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Non-Small Cell Lung Cancer
Interventions
Nivolumab, Chemotherapy, SBRT, Surgical Resection
Drug · Radiation · Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
4
States / cities
Baltimore, Maryland • Bel Air, Maryland • Glen Burnie, Maryland
Terminated Phase 3 Interventional Results available

Pulmonary Rehabilitation Before Lung Cancer Resection

NCT02887521
Conditions
Non-small Cell Lung Cancer (NSCLC), Chronic Obstructive Pulmonary Disease (COPD)
Interventions
education, rehabilitation, pedometer, surgery
Other · Procedure · Device
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
6
States / cities
Jacksonville, Florida • Chicago, Illinois • Detroit, Michigan + 3 more
Conditions
Borderline Resectable Pancreatic Adenocarcinoma
Interventions
Aglatimagene besadenovec, Chemoradiation, Stereotactic body radiation therapy, Surgery
Biological · Radiation · Procedure
Lead sponsor
Candel Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
2
States / cities
Fort Myers, Florida • Columbus, Ohio
Conditions
Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Resected Pancreatic Adenocarcinoma
Interventions
daraxonrasib
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
43
States / cities
Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 33 more
Conditions
Meningioma, Meningioma, Adult
Interventions
Avelumab, Proton Therapy, Surgery
Drug · Radiation · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Injury; Muscle, Ankle, and Foot, Multiple
Interventions
Preoperative mobility device(s) training
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Malignant Glioma
Interventions
Radiation Therapy, Radiosurgery, Stereotactic Biopsy, Temozolomide, Tumor Treating Fields Therapy, Magnetic Resonance Imaging, Biospecimen Collection, Biopsy, Therapeutic Conventional Surgery
Radiation · Procedure · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Phoenix, Arizona • Jacksonville, Florida
Terminated No phase listed Observational Results available

Alloantibodies in Pediatric Heart Transplantation

NCT01005316
Conditions
Pediatric Heart Transplantation, Pediatric Heart Transplant Recipients
Interventions
Induction Therapy, Tacrolimus, Mycophenolate Mofetil, Intraoperative plasma exchange/pheresis, Short-term post-operative plasmapheresis, Immunoglobulins, Intravenous, Prednisone
Drug · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 21 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
7
States / cities
Boston, Massachusetts • St Louis, Missouri • New York, New York + 4 more
Active, not recruiting Not applicable Interventional

3 Tesla MRI in Patients With Bladder Cancer

NCT00938145
Conditions
Bladder Cancer
Interventions
Specimen Ultra-High field MRI, chemotherapy, Cystectomy and Lymphadenectomy
Procedure · Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Advanced Fallopian Tube Carcinoma, Advanced Ovarian Carcinoma, Advanced Primary Peritoneal Carcinoma, Carcinomatosis, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Primary Peritoneal Cancer AJCC v7, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7
Interventions
Adavosertib, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
8
States / cities
Portland, Oregon • Conroe, Texas • Houston, Texas + 2 more
Conditions
Non Small Cell Lung Cancer
Interventions
Pembrolizumab, stereotactic radiation therapy (SRT), Surgery (Non-interventional, standard of care)
Drug · Radiation · Procedure
Lead sponsor
Sue Yom
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
San Francisco, California